Avacta gets approval for new cancer drug trial
Drug developer Avacta is to start a phase I study of its cancer drug, AVA6000, in a range of cancers to establish its safety, tolerability and effectiveness.
The Wetherby-based group has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a Clinical Trial Authorisation (CTA) in the UK for a phase I study of its lead pre|CISION pro-drug, AVA6000 pro-doxorubicin.
The new cancer drug, AVA6000, has been modified to make it inactive in the body's circulation until it enters a cancer tumour.
Advertisement
Hide AdAdvertisement
Hide Ad